On September 30, WUXI APPTEC rose 3.18% in regular trading, trading at 214.0 HKD/share, with turnover of approximately HKD 367 million.

On the news front, multiple positive catalysts converged to support the stock. BlackRock acquired approximately 1.167 million shares on the open market on September 24 at an average price of approximately HKD 179.83 per share, involving roughly HKD 210 million, lifting its stake from 4.96% to 5.16%. Separately, the company held its first extraordinary general meeting on September 29, at which all four proposals — including the employee stock ownership plan and charter amendments — were approved by a high vote margin, with shareholders representing 57.33% of voting shares participating. Additionally, the company's RMB 6.78 billion zero-coupon convertible bonds due 2027 have been fully converted into H shares, with the listing status on the Vienna Stock Exchange officially revoked on September 25, completely eliminating dilution overhang. Within the Life Sciences Tools & Services sector, peers also traded higher, with GENSCRIPT BIO up 9.76%, INSILICO up 9.84%, WUXI BIO up 4.21%, XTALPI up 4.75%, and WUXI XDC up 4.61%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)